OncologyDiscovery of tumor types highly susceptible to FASN inhibition and biomarker candidates for clinical analysis By Graviton / 04/2015 AACR Annual Meeting
OncologyBiomarker and PK/PD analyses of first-in-class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients By Graviton / 04/2015 AACR Annual Meeting
OncologyReport of a First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 By Graviton / 04/2015 AACR Annual Meeting
OncologyInitial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 By natalia / 11/2014 EORTC-NCI-AACR International Conference
OncologyMechanistic analysis of reversible FASN inhibition in preclinical tumor models identifies highly susceptible tumor types and enriches biomarker discovery for clinical applications By natalia / 11/2014 EORTC-NCI-AACR International Conference
OncologyEfficacy of FASN-selective small molecule inhibitors of preclinical tumor models By natalia / 04/2014 AACR Annual Meeting
OncologyCharacterization of small-molecule FASN inhibitors in preclinical tumor models By natalia / 10/2013 AACR-NCI-EORTC International Conference